Lucence’s Breast Cancer Test Seeks to Avoid Removing Healthy Tissue

BioWorld MedTech (Clarivate Analytics)
November 8, 2018

Singapore genomic medicine company Lucence Diagnostics Pte. Ltd. recently launched Fibrophyllo Tissue, which it claims is the world’s first molecular test to distinguish between breast fibroadenoma and phyllodes tumor. The aim is to help medical professionals determine if any breast tissue removals are needed. Breast fibroadenoma is the most common benign breast cancer and typically requires removal of the tumor. A phyllodes tumor, on the other hand, can be malignant and might recur after being removed, so a recommended treatment will involve the surgical removal of both the phyllodes tumor and the healthy breast tissue around it.

“It can be challenging to differentiate between the two types of breast tumors because they share overlapping clinical and histological features. Current immunohistochemical techniques are subjective and open to interpretation,” Dr Tan Min-Han, founder and CEO of Lucence, told BioWorld MedTech. He said that under the U.S. National Comprehensive Cancer Network 2018 Guidelines, the tumor and the surrounding tissue of 1 centimeter or more are recommended to be removed.

Dr Tan Min-Han was also the leader of the research team that invented the technology behind the tissue test, along with Prof Tan Puay Hoon at Singapore General Hospital (SGH). Funded by the Agency for Science, Technology and Research (A*STAR), the research went on for five years.

“This research collaboration will result in faster and more effective treatment for patients. Over 9,000 women were diagnosed with breast diseases in Singapore in the last five years. We aim to advance breast research to save more lives,” SGH’s Prof Tan Puay Hoon told BioWorld MedTech.

Lucence Diagnostics– To read the article in its entirety, please click here.

Need Help?